Why Appen, Cettire, DroneShield, and Imugene Shares Are Racing Higher
Why Appen, Cettire, DroneShield, and Imugene Shares Are Racing Higher
The Cettire share price is up 21% to $1.27. This morning, analysts at Bell Potter urged investors with a high tolerance for risk to buy this luxury products retailer's shares. According to the note, the broker has retained its speculative buy rating with a $2.00 price target. This still implies potential upside of almost 60% over the next 12 months even after today's gains. It said: "We continue to see plenty of upside in revenue/earnings from 3Q25 onwards considering overall improving demand conditions and benefits in CTT's lean business model, however with a higher near term risk profile priced into the name at current levels. Given the uncertainties ahead as the company resolves audit issues, we rate the stock as Speculative Buy."In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.2% to 8,074.4 points.
在下午交易时，标普/ASX 200指数（ASX：XJO）正朝着本周开盘下跌的方向走。截至撰写时，基准指数下跌了0.2%，至8074.4点。
Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:
以下列出了四只ASX股票，它们没有被拖后腿，这就是它们上涨的原因：
The Appen share price is up 5% to $1.05. This is despite there being no news out of the artificial intelligence data services company. However, it is worth noting that Appen's shares were sold off last week. This could mean that some investors believe they have been oversold and a buying opportunity has been created. The Appen share price remains down 20% since this time last week.
Appen的股价上涨了5%，达到了1.05美元。尽管这家人工智能数据服务公司没有任何新闻，但值得注意的是，Appen的股票上周被抛售了。这可能意味着一些投资者认为它们被抛售过度，出现了买入机会。Appen的股价自上周以来下跌了20%。
The Cettire share price is up 21% to $1.27. This morning, analysts at Bell Potter urged investors with a high tolerance for risk to buy this luxury products retailer's shares. According to the note, the broker has retained its speculative buy rating with a $2.00 price target. This still implies potential upside of almost 60% over the next 12 months even after today's gains. It said: "We continue to see plenty of upside in revenue/earnings from 3Q25 onwards considering overall improving demand conditions and benefits in CTT's lean business model, however with a higher near term risk profile priced into the name at current levels. Given the uncertainties ahead as the company resolves audit issues, we rate the stock as Speculative Buy."
Cettire的股价上涨了21%，达到了1.27美元。今天早上，贝尔·波特的分析师敦促高风险承受能力的投资者买入这家奢侈品零售商的股票。根据报告，经纪人保留了其预计的买入评级和2.00美元的目标价位。即使在今天的上涨之后，这仍然意味着在未来12个月内有将近60%的上涨空间。报告称：“考虑到整体需求状况的改善和CTT精益业务模式的好处，我们认为从2025年第3季度开始，收入/盈利有很大的上升空间，尽管目前股价已融入较高的近期风险配置。考虑到公司在解决审计问题方面面临的不确定性，我们将股票评级为预测性买入。”
The DroneShield share price is up 8% to $1.43. This counter drone technology company's shares have been on fire in recent sessions. This followed the release of a bullish broker note out of Bell Potter last week. It said: "We remain confident the company will deliver a significantly improved 2H performance based on 1) the significant level of inventory on hand to facilitate rapid fulfilment, 2) the historical seasonality of the business with >80% of CY23 revenue recorded in the 2H and 3) numerous near-term sales opportunities, including recently announced military aid packages." However, its price target of $1.35 has now been surpassed.
DroneShield的股价上涨了8%，达到了1.43美元。这家反无人机技术公司的股票在最近几个交易日表现出色。这是根据上周贝尔·波特发布的一份看好报告。报告称：“我们对该公司在下半年的业绩有很大信心，原因如下，首先，公司手头存货的数量非常大，可以快速交付；其次，业务在下半年的复季节性显著，年营业收入的80%以上是在下半年实现的；第三，有很多近期的销售机会，包括最近宣布的军事援助计划。”然而，1.35美元的目标价位已经被超过了。
$Imugene Ltd (IMU.AU)$
The Imugene share price is up 11% to 6.9 cents. Investors have been buying this clinical stage immuno-oncology company's shares after it announced promising results from a trial. The 1b clinical trial was testing Imugene's azer-cel (an allogeneic off-the-shelf CD19 CAR T) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). It is a type of non-Hodgkin's lymphoma (NHL).
Imugene的股价上涨11%，达到6.9美分。投资者在该公司宣布临床试验取得有望结果后纷纷购买该公司的股票。这项10亿人民币的临床试验是在复发/难治弥漫性大B细胞淋巴瘤（DLBCL）患者身上测试Imugene的azer-cel（一种异基因离体第19型CAR T细胞）的疗效。该病种属于非霍奇金淋巴瘤（NHL）的一种。
